期刊文献+

基因编辑在艾滋病治疗中的研究进展 被引量:2

Gene Therapy Strategies for the Treatment of HIV/AIDS
原文传递
导出
摘要 随着HIV病毒学研究的不断深入,传统抗反转录病毒治疗在HIV病毒清除和疾病治愈中的局限性日益凸显,因此通过基因编辑达到HIV病毒控制甚至完全治愈的策略倍受重视。目前基因编辑的研究主要包括以下两个方面:RNA水平的编辑技术和DNA水平的编辑技术。近年来包括锌指核酶技术(zinc finger nucleases,ZFN),转录激活样效应因子技术(transcription activatorlike effector nucleases,TALEN),成簇规律间隔短回文重复序列技术(clustered regulatory interspaced short palindromic repeat,CRISPR)和Ng Ago-g DNA技术在内的DNA编辑技术进展迅猛,并在HIV治疗中取得了长足的发展。本文比较了不同DNA水平编辑方法的特点和差异,综述了新一代基因编辑技术在HIV治疗中的进展以及潜在的医学应用前景。 With the further understanding of the molecular virological mechanisms of HIV pathogenesis, the limitation of traditional antiretroviral therapy for a cure of HIV is appearing. Therefore, gene therapy has attracted more and more attention. Currently, two kinds ofgene editing strategies for gene therapy were based on RNA and DNA respectively. The latter includes ZFN (zinc finger nucleases), TALEN(transcription activator-like effector nucleases), CRISPR(clustered regulatory interspaced short palindromic repeat) and NgAgo-gDNA, which lead the development of gene editing and achieve great success in HIV therapy. In this review, we first compare the specialty and distinction between different DNA editing methods, and then summarize the advances and prospects of these new methods in HIV gene therapy.
出处 《现代生物医学进展》 CAS 2017年第35期6984-6987,6996,共5页 Progress in Modern Biomedicine
基金 国家"十二五"科技重大专项(2014ZX10001002) 国家自然科学基金青年基金项目(81501041)
关键词 艾滋病 基因编辑 ZFN CRISPR NgAgo AIDS Gene therapy ZFN CRISPR NgAgo
  • 相关文献

参考文献2

二级参考文献52

  • 1Antiretroviral Therapy Cohort C. Life expectancy of individuals on com- bination antiretroviral therapy in high-income countries:a collaborative analysis of 14 cohort studies[J]. Lancet,2008,372(9635):293-299.
  • 2Churchill M J, Gorry PR, Cowley D, et al. Use of laser capture micro- dissection to detect integrated HIV-1 DNA in macrophages and astro- cytes from autopsy brain tissues [ J ]. Journal of neurovirology, 2006, 12(2) :146-152.
  • 3North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretreviral therapy in a nonhuman primate model for AIDS [ J]. J Virol,2010,84(6) :2913-2922.
  • 4Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy [ J ]. The Journal of infectious disea- ses,2010,202(10) :1553-1561.
  • 5Chun TW ,Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretreviral therapy despite profoundly low levels of HIV reservoir: implications for eradication [ J ]. Aids, 2010, 24 ( 18 ) : 2803-2808.
  • 6Bongiovanni M, Casana M, Tineati C, et al. Treatment interruptions in HIV-infected subjects[ J ]. The Journal of antimicrobial chemothera- py,2006,58 ( 3 ) :502-505. (10) :1598-1601.
  • 7Hutter G, Nowak D, Mossner M, et al. Long-term control of I-IIV by CCR5 Deha32/Deha32 stem-cell transplantation[ J]. The New Eng- land journal of medicine,2009,360(7) :692-698.
  • 8Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individu- als[ J]. Science,2010,329(5988) :174-180.
  • 9Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term im- munovirologic control following antiretreviral therapy interruption in patients treated at the time of primary HIV-1 infection [ J ]. Aids, 2010,24.
  • 10Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV- 1 controllers with a long-term virological remission after the interrup- tion of early initiated antiretroviral therapy ANRS VISCONTI Study [ J ]. PLoS pathogens,2013,9 (3) : e1003211.

共引文献5

同被引文献8

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部